A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Peripheral Vascular Surgery
Fibrin Sealant Grifols
+ Manual Compression
Étude thérapeutique
Résumé
Date de début de l'étude : 1 août 2012
Date à laquelle le premier participant a commencé l'étude.The purpose of this study is to demonstrate that the application of Fibrin Sealant Grifols provides a measurable benefit when compared to hemostasis achieved through conventional surgical technique (suture) and by standard hemostatic action, such as mechanical pressure through manual compression. This study has a Preliminary Part (I) in which all subjects are treated with Fibrin Sealant Grifols and a Primary Part (II) in which subjects are randomized in a 2:1 ratio to either Fibrin Sealant Grifols or manual compression.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.225 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Critères
Inclusion Criteria: Hemoglobin (Hgb) ≥ 8.0 g/dL at Baseline (within 24 hours prior to surgical procedure). Require elective (non-emergency), primary, open (non-laparoscopic; non-endovascular) peripheral vascular surgery. Require one of the following peripheral vascular procedures involving proximal end-to-side arterial anastomosis utilizing coated or uncoated Polytetrafluoroethylene grafts: a) Femoral-femoral bypass grafting, b) Femoral-popliteal bypass grafting, c) Femoral-distal bypass grafting, d) Ilio-iliac bypass grafting, e) Ilio-femoral bypass grafting, f) Ilio-popliteal bypass grafting, g) Aorto-iliac bypass grafting, h) Aorto-femoral bypass grafting, i)Axillo-femoral bypass grafting, and j) Upper extremity vascular access for hemodialysis. A target bleeding site can be identified. Target bleeding site has moderate arterial bleeding. Exclusion Criteria: Undergoing a re-operative procedure. Undergoing other vascular procedures during the same surgical session (stenting and/or endarterectomy of the same artery are allowed). Have an infection in the anatomic surgical area. Have a history of severe (e.g. anaphylactic) reactions to blood or to any blood-derived product. Have previous known sensitivity to any Fibrin Sealant Grifols, heparin, or protamine component. Females who are pregnant or nursing a child at Baseline (within 24 hours prior to surgical procedure). Have undergone a therapeutic surgical procedure within 30 days from the screening visit. Target bleeding site cannot be identified. Target bleeding site has mild or severe arterial bleeding. Occurrence of major intraoperative complications that require resuscitation or deviation from the planned surgical procedure. Intraoperative change in planned surgical procedure, which results in subject no longer meeting preoperative inclusion and/or exclusion criteria.
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.2 groupes d'intervention sont désignés dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Groupe I
ExpérimentalGroupe II
Comparateur actifObjectifs de l'étude
Objectifs principaux
Objectifs secondaires
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 38 sites
125
Palo Alto, United States119
San Diego, United States149
Jacksonville, United States